Entero Therapeutics, Inc.
ENTO
$0.54
$0.055711.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -90.57% | -54.03% | -30.41% | 13.36% | 216.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -90.97% | -70.60% | -44.87% | -18.07% | 123.98% |
| Operating Income | 90.97% | 70.60% | 44.87% | 18.07% | -123.98% |
| Income Before Tax | 89.58% | 70.88% | 44.81% | 18.12% | -123.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.46% | -187.71% | 44.81% | -83.46% | 241.51% |
| Earnings from Discontinued Operations | -61.57% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -122.62% | -198.43% | 24.84% | -110.25% | 236.77% |
| EBIT | 90.97% | 70.60% | 44.87% | 18.07% | -123.98% |
| EBITDA | 91.00% | 69.71% | 44.79% | 18.77% | -124.08% |
| EPS Basic | -109.01% | 39.57% | 93.64% | 89.78% | 108.56% |
| Normalized Basic EPS | 96.15% | 109.14% | 95.41% | 95.95% | 85.53% |
| EPS Diluted | -189.01% | 39.57% | 93.64% | 89.78% | 101.01% |
| Normalized Diluted EPS | 68.26% | 109.14% | 95.41% | 95.95% | 98.24% |
| Average Basic Shares Outstanding | 170.43% | 339.92% | 1,103.28% | 1,921.32% | 1,445.61% |
| Average Diluted Shares Outstanding | -67.16% | 339.92% | 1,103.28% | 1,921.32% | 12,629.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |